NewsRoom Articles - Page 2 of 214

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

TuesdaySep 09, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL. Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease. Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that…

TuesdaySep 09, 2025 10:00 am

Senior NIH Officials Allege Retaliation as Motive for Their Ouster

Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week. Back in April, Kathleen Neuzil and Jeanne Marazzo were put on administrative leave from their NIH top positions. In their complaints filed last week at the United States Office of Special Counsel, they claim that the work environment at the NIH after Robert F. Kennedy Jr. took over as HHS Secretary became hostile to…

MondaySep 08, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Nutriband sustains itself through multiple revenue-generating subsidiaries At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents…

MondaySep 08, 2025 10:30 am

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Advancing Dedicated Breast Imaging at a Market Crossroads

IzoView Breast CT designed as the first breast-dedicated CT imaging system to eliminate tissue overlap and compression limitations specifically for breast cancer screening in patients with dense breast tissue Platform model supports multiple future clinical applications, including diagnosis and treatment planning without hardware replacement Regulatory pathway alignment and commercialization planning position Izotropic for potential market entry into a $8.7B global breast imaging sector Imaging’s Stagnation Meets a New Wave of Purpose-Built Devices For decades, breast cancer screening has relied heavily on mammography, a compression-based modality that, while valuable, carries persistent shortcomings. Dense breast tissue, which affects nearly half of women,…

FridaySep 05, 2025 10:00 am

NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers

The NCI, or National Cancer Institute, a federal body, has revealed that it will no longer fund a program that has been running for 26 years focused on advancing clinical studies on children with brain cancers. The group, Pediatric Brain Tumor Consortium, was founded in 1999 to bring together 15 academic institutions and pediatric hospitals within the United States and Canada to conduct early-stage clinical trials (Phase 1 and Phase 2). This consortium has a record of conducting trials aimed at exploring new therapies, strategies for delivering radiation treatment, and finding new technologies to deliver treatments specifically focused on pediatric…

ThursdaySep 04, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile. CEO notes that “the FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.” Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing. Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only…

ThursdaySep 04, 2025 10:00 am

Research Uncovers Possible Way to Repair Myelin in MS Patients

According to new research published in the journal Cell, targeting the SOX6 protein could open a new way to repair myelin in individuals afflicted by multiple sclerosis. According to the researchers, this SOX6 protein regulates the maturation of cells referred to as oligodendrocytes which manufacture myelin. The team found that when SOX6 is overactive, as is the case in MS patients, oligodendrocytes remain immature and can’t therefore produce myelin. By targeting SOX6, the researchers believe that myelin production can resume and consequently some form of restoration in function could be achieved in patients. In healthy people, SOX6 is less active,…

WednesdaySep 03, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’

The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors. A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle(TM). A strategic partnership with Shanghai Medicilon supports rapid IND filings for up to 20 drug candidates, significantly accelerating development timelines. Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency. The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile…

TuesdaySep 02, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Building Market Awareness Through Strategic Education Platform

BreastCT.com launches as a comprehensive educational resource focused on dedicated breast CT technology and IzoView's clinical advantages for dense breast tissue imaging Platform designed to evolve alongside company progression through clinical studies, regulatory phases, and commercial launch milestones Strategic positioning within successful imaging category creation context provides clear market reference framework for IzoView's commercial potential The Pre-Commercial Challenge: Educating Markets on Breakthrough Technology Medical device companies developing breakthrough technologies face a fundamental commercialization challenge beyond regulatory approval: market education. When innovations represent genuine advances over existing standards of care, successful adoption requires comprehensive stakeholder education across patients, clinicians, and healthcare…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

Senior NIH Officials Allege Retaliation as Motive for Their Ouster

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Advancing Dedicated Breast Imaging at a Market Crossroads

NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

Research Uncovers Possible Way to Repair Myelin in MS Patients

Oncotelic Therapeutics Inc. (OTLC) Is ‘One to Watch’

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Building Market Awareness Through Strategic Education Platform

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search